Hester Biosciences Limited (HESTERBIO.BO)
INR 1693.5
(2.36%)
INR 1693.5
(2.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.27 Billion INR | -29.35% |
| 2022 | 1.8 Billion INR | 10.96% |
| 2021 | 1.62 Billion INR | 4.58% |
| 2020 | 1.55 Billion INR | 7.23% |
| 2019 | 1.44 Billion INR | 15.3% |
| 2018 | 1.25 Billion INR | 35.8% |
| 2017 | 925.28 Million INR | 17.09% |
| 2016 | 790.24 Million INR | -1.11% |
| 2015 | 799.07 Million INR | 22.27% |
| 2014 | 653.55 Million INR | 41.93% |
| 2013 | 460.47 Million INR | 14.18% |
| 2012 | 403.29 Million INR | 25.74% |
| 2011 | 320.74 Million INR | -21.89% |
| 2010 | 410.61 Million INR | 87.02% |
| 2009 | 219.56 Million INR | 15.26% |
| 2008 | 190.5 Million INR | -15.25% |
| 2007 | 224.78 Million INR | 85.58% |
| 2006 | 121.12 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 591.75 Million INR | 0.99% |
| 2024 Q1 | 386.97 Million INR | 2.18% |
| 2023 Q4 | 378.7 Million INR | -18.28% |
| 2023 FY | 1.27 Billion INR | -29.35% |
| 2023 Q1 | 536.82 Million INR | 44.9% |
| 2023 Q3 | 463.44 Million INR | -9.0% |
| 2023 Q2 | 509.29 Million INR | -5.13% |
| 2022 Q3 | 546.72 Million INR | 6.77% |
| 2022 Q4 | 370.48 Million INR | -32.24% |
| 2022 FY | 1.8 Billion INR | 10.96% |
| 2022 Q1 | 357.66 Million INR | 13.41% |
| 2022 Q2 | 512.04 Million INR | 43.16% |
| 2021 Q4 | 315.36 Million INR | -25.59% |
| 2021 FY | 1.62 Billion INR | 4.58% |
| 2021 Q2 | 465.1 Million INR | 9.88% |
| 2021 Q3 | 423.82 Million INR | -8.88% |
| 2021 Q1 | 423.27 Million INR | 12.08% |
| 2020 Q4 | 377.65 Million INR | -12.62% |
| 2020 FY | 1.55 Billion INR | 7.23% |
| 2020 Q3 | 432.17 Million INR | 9.46% |
| 2020 Q2 | 394.81 Million INR | 17.84% |
| 2020 Q1 | 335.04 Million INR | 173.05% |
| 2019 Q3 | 448.77 Million INR | 16.2% |
| 2019 Q4 | 122.7 Million INR | -72.66% |
| 2019 FY | 1.44 Billion INR | 15.3% |
| 2019 Q1 | 391.83 Million INR | 166.47% |
| 2019 Q2 | 386.22 Million INR | -1.43% |
| 2018 Q3 | 386.03 Million INR | 0.97% |
| 2018 Q2 | 382.31 Million INR | 12.07% |
| 2018 Q1 | 341.14 Million INR | 0.0% |
| 2018 FY | 1.25 Billion INR | 35.8% |
| 2018 Q4 | 147.04 Million INR | -61.91% |
| 2017 FY | 925.28 Million INR | 17.09% |
| 2016 FY | 790.24 Million INR | -1.11% |
| 2015 FY | 799.07 Million INR | 22.27% |
| 2014 FY | 653.55 Million INR | 41.93% |
| 2013 FY | 460.47 Million INR | 14.18% |
| 2012 Q4 | 94.81 Million INR | -21.05% |
| 2012 FY | 403.29 Million INR | 25.74% |
| 2012 Q1 | 89.2 Million INR | 0.0% |
| 2012 Q2 | 99.18 Million INR | 11.19% |
| 2012 Q3 | 120.09 Million INR | 21.08% |
| 2011 FY | 320.74 Million INR | -21.89% |
| 2010 FY | 410.61 Million INR | 87.02% |
| 2009 FY | 219.56 Million INR | 15.26% |
| 2008 FY | 190.5 Million INR | -15.25% |
| 2007 FY | 224.78 Million INR | 85.58% |
| 2006 FY | 121.12 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 95.244% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.177% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 89.756% |
| Granules India Limited | 16.79 Billion INR | 92.418% |
| Indoco Remedies Limited | 6.04 Billion INR | 78.918% |
| Achyut Healthcare Limited | 4.86 Million INR | -26101.399% |
| Ajanta Pharma Limited | 21.06 Billion INR | 93.953% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.565% |
| Alpa Laboratories Limited | 188.89 Million INR | -574.263% |
| Brooks Laboratories Limited | 65.62 Million INR | -1840.948% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 79.532% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 13.463% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 65.535% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.222% |
| Eris Lifesciences Limited | 10.42 Billion INR | 87.785% |
| FDC Limited | 8.33 Billion INR | 84.719% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.163% |
| Gufic Biosciences Limited | 4.16 Billion INR | 69.44% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 79.439% |
| Ipca Laboratories Limited | 29.8 Billion INR | 95.727% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -95.168% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -560.857% |
| Lasa Supergenerics Limited | 121.02 Million INR | -952.342% |
| Laurus Labs Limited | 24.62 Billion INR | 94.827% |
| Lupin Limited | 123.71 Billion INR | 98.971% |
| Mankind Pharma Limited | 44.52 Billion INR | 97.139% |
| Medicamen Biotech Limited | 495.49 Million INR | -157.046% |
| Medico Remedies Limited | 262.14 Million INR | -385.859% |
| Megasoft Limited | 342.07 Million INR | -272.335% |
| NATCO Pharma Limited | 25.73 Billion INR | 95.051% |
| Piramal Pharma Limited | 24.47 Billion INR | 94.795% |
| RPG Life Sciences Limited | 2.48 Billion INR | 48.705% |
| Sigachi Industries Limited | 2 Billion INR | 36.39% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.507% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 69.111% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -35.15% |
| Unichem Laboratories Limited | 4.86 Billion INR | 73.82% |
| Wanbury Limited | 1.73 Billion INR | 26.406% |
| Windlas Biotech Limited | 1.33 Billion INR | 4.866% |
| ZIM Laboratories Limited | 1.26 Billion INR | -0.534% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.983% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 311.427% |
| Divi's Laboratories Limited | 32.44 Billion INR | 96.074% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 77.97% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 18.174% |
| Bal Pharma Limited | 770.19 Million INR | -65.367% |
| Strides Pharma Science Limited | 14.38 Billion INR | 91.148% |
| Venus Remedies Limited | 2.18 Billion INR | 41.645% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 78.159% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 57.146% |
| Shilpa Medicare Limited | 3.54 Billion INR | 64.091% |
| Aarti Drugs Limited | 8.31 Billion INR | 84.685% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 72.196% |
| Suven Life Sciences Limited | -200.79 Million INR | 734.297% |
| Ind-Swift Limited | 2.17 Billion INR | 41.375% |
| Valiant Laboratories Limited | -60.66 Million INR | 2199.515% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 94.389% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -47.892% |
| Themis Medicare Limited | 1.5 Billion INR | 15.31% |
| Hikal Limited | 3.14 Billion INR | 59.478% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 97.276% |
| Sequent Scientific Limited | 2.97 Billion INR | 57.242% |
| Novartis India Limited | 1.32 Billion INR | 4.013% |
| Wockhardt Limited | 16.24 Billion INR | 92.157% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 93.516% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -8635.776% |
| Neuland Laboratories Limited | 8.24 Billion INR | 84.558% |
| Morepen Laboratories Limited | 6.16 Billion INR | 79.328% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -105.269% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -81.018% |